Presentation is loading. Please wait.

Presentation is loading. Please wait.

1 National Estimates from the Drug Abuse Warning Network CAPT Kathy Poneleit United States Public Health Service Office of Applied Studies Substance Abuse.

Published byBrent Simon Modified over 8 years ago

Similar presentations

Presentation on theme: "1 National Estimates from the Drug Abuse Warning Network CAPT Kathy Poneleit United States Public Health Service Office of Applied Studies Substance Abuse."— Presentation transcript:

1 1 National Estimates from the Drug Abuse Warning Network CAPT Kathy Poneleit United States Public Health Service Office of Applied Studies Substance Abuse & Mental Health Services Administration November 13, 2008 http://DAWNinfo.samhsa.gov

2 SAMHSA/OAS 2 Today's Agenda  No conflicts of interest  Overview of DAWN  Key findings from 2007 –Nonmedical use of opiates/opioids –2004-2007 comparisons –Extended- vs. immediate-release oxycodone –Extended- vs. immediate-release morphine

3 SAMHSA/OAS 3 DAWN Survey Design  Stratified probability sample of hospitals –Short-term, general, non-Federal hospitals with 24-hour emergency departments (EDs)  National estimates account for: –Sample design –Unit nonresponse –Partial nonresponse in responding hospital

4 SAMHSA/OAS 4 National Estimates Oversample areas (urban) + Remainder area (urban & rural)

5 SAMHSA/OAS 5 Source of DAWN Estimates, 2004-2007 2004200520062007 Eligible hospitals4,5054,5494,5684,575 Sample of hospitals556562544542 Responding hospitals220224205207 Response rate39.639.937.738.2 Drug-related ED visits2,537,7223,009,0253,441,8553,998,228 Drugs reports4,047,1354,624,4555,384,8176,247,718

6 SAMHSA/OAS 6 DAWN Data Collection: Retrospective Review of Medical Records Source: DAWN, 2007 data, 11/11/2008 National estimates Charts reviewed 10,038,897 Cases found 375,031 Drug-related ED visits reviewed ED visits not reviewed

7 SAMHSA/OAS 7 Analysis Domains Drug-related ED visits Medical use Pharmaceuticals Nonmedical use Pharmaceuticals Illicit drugs Alcohol

8 SAMHSA/OAS 8 Definition: Nonmedical Use of Pharmaceuticals  Based on retrospective chart review –Exceeded prescribed or recommended dose –Used drugs prescribed for another –Malicious poisoning –Substance abuse –Excludes drug-related suicide attempts –Includes suicide ideation, plan, gesture

9 SAMHSA/OAS 9 Drug-Related ED Visit Rates, 2004-2007 Source: National estimates from DAWN, 2004-2007 No significant change*Significant change, 2004 vs. 2007 2005 vs. 2007 2006 vs. 2007

10 SAMHSA/OAS 10 Oxycodone Controlled and Immediate Release

11 SAMHSA/OAS 11 Nonmedical Use of Pharmaceuticals, Selected Opiates/Opioids, 2007 Source: National estimates from DAWN, 2007 * Single- & multi-ingredient formulations CI lower bound Estimate CI upper bound

12 SAMHSA/OAS 12 Nonmedical Use of Pharmaceuticals, Selected Opiates/Opioids, 2007 Source: National estimates from DAWN, 2007 * Single- & multi-ingredient formulations CI lower bound Estimate CI upper bound

13 SAMHSA/OAS 13 Classification of Oxycodone Reports  Controlled release (CR) –OxyContin (99%) Alternate terms: –Generic OxyContin –Teva OxyContin –Impax OxyContin –Oxycodone CR –Oxycodone ER –Oxycodone SR  Immediate release (IR) –acetaminophen-oxy e.g., Percocet (92%) –aspirin-oxy e.g., Percodan –ibuprofen-oxy e.g., Combunox –oxycodone e.g., Roxicodone

14 SAMHSA/OAS 14 Classification of Oxycodone Reports (cont'd)  Unknown release type (UK) –Oxycodone (95%) alternate terms: –Free oxycodone –M-Oxy –Oxycodone hydrochloride –Oxycodone metabolites

15 SAMHSA/OAS 15 Nonmedical Use of Pharmaceuticals, Oxycodone, by Release Type, 2004-2007 Source: National estimates from DAWN, 2004-2007 CI lower bound Estimate CI upper bound ControlledImmediate Unknown

16 SAMHSA/OAS 16 Oxycodone, CR vs. IR – All Visits Source: DAWN estimates for the U.S., 2004-2007 *Significant change, 2004 vs. 2007 2005 vs. 2007 2006 vs. 2007 No significant change 2004 2005 2006 2007

17 SAMHSA/OAS 17 Oxycodone, CR vs. IR – Medical Use Source: DAWN estimates for the U.S., 2004-2007 *Significant change, 2004 vs. 2007 2005 vs. 2007 2006 vs. 2007 No Significant change 2004 2005 2006 2007

18 SAMHSA/OAS 18 Oxycodone, CR vs. IR – Nonmedical Use Source: DAWN estimates for the U.S., 2004-2007 *Significant change, 2004 vs. 2007 2005 vs. 2007 No significant change 2006 vs. 2007 2004 2005 2006 2007

19 SAMHSA/OAS 19 Oxycodone, CR vs. IR Source: DAWN estimates for the U.S., 2004-2007 % of visits Nonmedical useMedical use

20 SAMHSA/OAS 20 Nonmedical Use: Hydrocodone and Oxycodone by Release Type, 2004-2007 Source: DAWN estimates for the U.S., 2004-2006 Hydrocodone UK ER IR Oxycodone:

21 SAMHSA/OAS 21 Nonmedical Use: All Opiates/Opioids, ED Visit Rates, 2007 ED visits per 100K population Age Source: DAWN estimates for the U.S., 2007

22 SAMHSA/OAS 22 Nonmedical Use: All Hydrocodone, ED Visit Rates, 2007 ED visits per 100K population Age Source: DAWN estimates for the U.S., 2007

23 SAMHSA/OAS 23 Nonmedical Use: All Oxycodone, ED Visit Rates, 2007 ED visits per 100K population Age Source: DAWN estimates for the U.S., 2007

24 SAMHSA/OAS 24 Nonmedical Use: Oxycodone CR, ED Visit Rates, 2007 ED visits per 100K population Age Source: DAWN estimates for the U.S., 2007

25 SAMHSA/OAS 25 Nonmedical Use: Oxycodone IR, ED Visit Rates, 2007 ED visits per 100K population Age Source: DAWN estimates for the U.S., 2007

26 SAMHSA/OAS 26 Nonmedical Use: Oxycodone UK, ED Visit Rates, 2007 ED visits per 100K population Age Source: DAWN estimates for the U.S., 2007

27 SAMHSA/OAS 27 Nonmedical Use: Disposition from ED, Oxycodone by Release Type, 2007 Source: DAWN estimates for the U.S., 2007 % of ED visits ControlledUnknownImmediate Some follow-up No evidence of follow-up care

28 SAMHSA/OAS 28 Nonmedical Use: Number of Drugs, Oxycodone by Release Type, 2007 Source: DAWN estimates for the U.S., 2007 % of ED visits ControlledUnknownImmediate 1 drug Multiple drugs

29 SAMHSA/OAS 29 Nonmedical Use ED Visits: Conclusions  Opioid analgesics nearing 287,000 visits –¼ Oxycodone ¼ Hydrocodone –  in immediate and unknown release types  Highest visit rates in patients aged 21-54  Majority of patients treated and released  Polydrug use was higher for immediate versus controlled release

30 SAMHSA/OAS 30 Morphine Controlled and Immediate Release

31 SAMHSA/OAS 31 Nonmedical Use of Pharmaceuticals, Selected Opiates/Opioids, 2007 Source: National estimates from DAWN, 2007 * Single- & multi-ingredient formulations CI lower bound Estimate CI upper bound

32 SAMHSA/OAS 32 Classification of Morphine Reports  Controlled release (CR) –MS Contin (71%) Alternate terms: –Avinza –Kadian –Morphine Sulfate SR –Oramorph SR –Morphine Extended Release –Morphine Patches  Immediate release (IR) –Morphine Sulfate –Morphine Pill –Morphine IR –Morphine Rapi-Ject –Roxanol –Morphelan

33 SAMHSA/OAS 33 Nonmedical Use of Pharmaceuticals, Morphine, by Release Type, 2004-2007 Source: National estimates from DAWN, 2004-2007 CI lower bound Estimate CI upper bound Controlled Immediate

34 SAMHSA/OAS 34 Morphine, CR vs. IR – All Visits Source: DAWN estimates for the U.S., 2004-2007 *Significant change, 2004 vs. 2007 2005 vs. 2007 2006 vs. 2007 No significant change 2004 2005 2006 2007

35 SAMHSA/OAS 35 Morphine, CR vs. IR – Medical Use Source: DAWN estimates for the U.S., 2004-2007 *Significant change, 2004 vs. 2007 2005 vs. 2007 2006 vs. 2007 No Significant change

36 SAMHSA/OAS 36 Morphine, CR vs. IR – Nonmedical Use Source: DAWN estimates for the U.S., 2004-2007 *Significant change, 2004 vs. 2007 2005 vs. 2007 No significant change 2006 vs. 2007

37 SAMHSA/OAS 37 Morphine, CR vs. IR Source: DAWN estimates for the U.S., 2004-2007 % of visits Nonmedical useMedical use

38 SAMHSA/OAS 38 Nonmedical Use: Hydrocodone and Morphine by Release Type, 2004-2007 Source: DAWN estimates for the U.S., 2004-2006 Hydrocodone UK CR IR Morphine:

39 SAMHSA/OAS 39 Nonmedical Use: All Morphine, ED Visit Rates, 2007 ED visits per 100K population Age Source: DAWN estimates for the U.S., 2007

40 SAMHSA/OAS 40 Nonmedical Use: Morphine CR, ED Visit Rates, 2007 ED visits per 100K population Age Source: DAWN estimates for the U.S., 2007

41 SAMHSA/OAS 41 Nonmedical Use: Morphine IR, ED Visit Rates, 2007 ED visits per 100K population Age Source: DAWN estimates for the U.S., 2007

42 SAMHSA/OAS 42 Nonmedical Use: Disposition from ED, Morphine by Release Type, 2007 Source: DAWN estimates for the U.S., 2007 % of ED visits ControlledUnknownImmediate Some follow-up No evidence of follow-up care

43 SAMHSA/OAS 43 Nonmedical Use: Number of Drugs, Morphine by Release Type, 2007 Source: DAWN estimates for the U.S., 2007 % of ED visits ControlledUnknownImmediate 1 drug Multiple drugs

44 SAMHSA/OAS 44 Nonmedical Use ED Visits: Conclusions  Morphine related ED visits nearing 30,000 –Immediate release  –Controlled release is similar 2004-2007  Highest visit rates in patients aged 21-54  Majority of patients treated and released  Polydrug use is typical

45 SAMHSA/OAS 45 Important Considerations: DAWN Depends on ED Medical Records  Link between ED visit and use of drug  Dose levels and source of drug unavailable  Nonspecific drug reports –Opiates/opioids, unspecified (unnamed) –Unknown release-type  Unique names for immediate versus extended release enable better surveillance

46 SAMHSA/OAS 46 Acknowledgements  Rong Cai, Statistician

Download ppt "1 National Estimates from the Drug Abuse Warning Network CAPT Kathy Poneleit United States Public Health Service Office of Applied Studies Substance Abuse."

Similar presentations

CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for Substance Abuse Research February 4, 2013 Vol.

CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for Substance Abuse Research February 4, 2013 Vol.
OPIOIDS I. Where do they come from? / synthesized in 1803

OPIOIDS I. Where do they come from? / synthesized in 1803
Delay from Testing HIV Positive until First HIV Care for Drug Users: Adverse Consequences and Possible Solutions Barbara J Turner MD, MSEd* John Fleishman.

Delay from Testing HIV Positive until First HIV Care for Drug Users: Adverse Consequences and Possible Solutions Barbara J Turner MD, MSEd* John Fleishman.
San Francisco Bay Area Drug Trends and Effective Intervention Strategies Alice Gleghorn, Ph.D County Alcohol and Drug Program Administrator San Francisco.

San Francisco Bay Area Drug Trends and Effective Intervention Strategies Alice Gleghorn, Ph.D County Alcohol and Drug Program Administrator San Francisco.
National Institute on Drug Abuse P rescription D rug A buse: An Escalating Public Health Threat P rescription D rug A buse: An Escalating Public Health.

National Institute on Drug Abuse P rescription D rug A buse: An Escalating Public Health Threat P rescription D rug A buse: An Escalating Public Health.
Overview of the Clinical Development EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use. ASENT 12 th Annual.

Overview of the Clinical Development EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use. ASENT 12 th Annual.
Prevalence and Patterns of Nonmedical Use of OxyContin ® and Other Pain Relievers Joe Gfroerer Office of Applied Studies Substance Abuse and Mental Health.

Prevalence and Patterns of Nonmedical Use of OxyContin ® and Other Pain Relievers Joe Gfroerer Office of Applied Studies Substance Abuse and Mental Health.
Findings from the Drug Abuse Warning Network Narcotic Analgesics Judy K. Ball, Ph.D., M.P.A. Office of Applied Studies, Substance Abuse and Mental Health.

Findings from the Drug Abuse Warning Network Narcotic Analgesics Judy K. Ball, Ph.D., M.P.A. Office of Applied Studies, Substance Abuse and Mental Health.
William A. Lanier, DVM, MPH Kristina Russell, MPH Utah Department of Health Risk Factors for Prescription Opioid Death – Utah, 2008–2009 Office of Surveillance,

William A. Lanier, DVM, MPH Kristina Russell, MPH Utah Department of Health Risk Factors for Prescription Opioid Death – Utah, 2008–2009 Office of Surveillance,
Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 Reported Manipulation of Oxycodone Extended-Release.

Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 Reported Manipulation of Oxycodone Extended-Release.
Sublingual Buprenorphine and Pain

Sublingual Buprenorphine and Pain
Results of the 2002 Emergency Pediatric Services and Equipment Supplement (EPSES) to the National Hospital Medical Care Survey (NHAMCS) Centers for Disease.

Results of the 2002 Emergency Pediatric Services and Equipment Supplement (EPSES) to the National Hospital Medical Care Survey (NHAMCS) Centers for Disease.
Anesthetic and Life Support Drugs, and Drug Safety and Risk Management Advisory Committees, November 13, 2008 Outpatient Drug Utilization Trends for Oxycodone.

Anesthetic and Life Support Drugs, and Drug Safety and Risk Management Advisory Committees, November 13, 2008 Outpatient Drug Utilization Trends for Oxycodone.
Www.aodhealth.org1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2007.

Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2007.
Controlled Substance Prescribing Trends and Physician and Pharmacy Utilization Patterns: Epidemiological Analysis of the Maine Prescription Monitoring.

Controlled Substance Prescribing Trends and Physician and Pharmacy Utilization Patterns: Epidemiological Analysis of the Maine Prescription Monitoring.
Health Care The following entities provided data for the Health Care Section of the Community Assessment:  Jefferson County CAD System  Samaritan Medical.

Health Care The following entities provided data for the Health Care Section of the Community Assessment:  Jefferson County CAD System  Samaritan Medical.
1 Adolescent Mental Health: Key Data Indicators Gwendolyn J. Adam, Ph.D., L.C.S.W. Assistant Professor - Department of Pediatrics Section of Adolescent.

1 Adolescent Mental Health: Key Data Indicators Gwendolyn J. Adam, Ph.D., L.C.S.W. Assistant Professor - Department of Pediatrics Section of Adolescent.
Lock Your Meds BE AWARE. DON'T SHARE. Sponsored by.

Lock Your Meds BE AWARE. DON'T SHARE. Sponsored by.
Serving our community by improving health The Addiction Crisis November 2014.

Serving our community by improving health The Addiction Crisis November 2014.
Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.

Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.

Similar presentations

Ads by Google